Nassani Momen, Fakih Riad El, Passweg Jakob, Cesaro Simone, Alzahrani Hazzaa, Alahmari Ali, Bonfim Carmem, Iftikhar Raheel, Albeihany Amal, Halkes Constantijn, Ahmed Syed Osman, Dufour Carlo, Aljurf Mahmoud
Department of Hematology, Stem Cell Transplant & Cellular Therapy, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
Department of Hematology, University Hospital Basel, Basel, Switzerland.
Front Oncol. 2023 May 8;13:1135160. doi: 10.3389/fonc.2023.1135160. eCollection 2023.
Bone marrow failure syndromes are a heterogeneous group of diseases. With the major advancements in diagnostic tools and sequencing techniques, these diseases may be better classified and therapies may be further tailored. Androgens, a historic group of drugs, were found to stimulate hematopoiesis by enhancing the responsiveness of progenitors. These agents have been used for decades to treat different forms of bone marrow failure. With the availability of more effective pathways to treat BMF, androgens are less used currently. Nevertheless, this group of drugs may serve BMF patients where standard therapy is contraindicated or not available. In this article, we review the published literature addressing the use of androgens in BMF patients and we make recommendations on how to best use this class of drugs within the current therapeutic landscape.
骨髓衰竭综合征是一组异质性疾病。随着诊断工具和测序技术的重大进展，这些疾病可能会得到更好的分类，治疗方法也可能会进一步优化。雄激素是一类历史悠久的药物，被发现可通过增强祖细胞的反应性来刺激造血。这些药物已被用于治疗不同形式的骨髓衰竭数十年。随着治疗骨髓衰竭更有效途径的出现，目前雄激素的使用较少。然而，在标准治疗禁忌或不可用时，这类药物可能对骨髓衰竭患者有用。在本文中，我们回顾了已发表的关于雄激素在骨髓衰竭患者中应用的文献，并就如何在当前治疗格局中最佳使用这类药物提出建议。
